A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Saxagliptin (ONGLYZA)

Saxagliptin and metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical S....

First FDA approval2014-11-20
Generic availableYes · 3 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$24.2M in CY2024 Part D spend81K claims · 27K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.34/unit
12 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.43
Across all dosage forms in distribution.
Highest NADAC
$1.52
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Saxagliptin used for?

Saxagliptin and metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical S....

Is there a generic for Saxagliptin?

Yes. 6 ANDAs filed at FDA, 3 generic manufacturers currently shipping.

How much does my plan pay for Saxagliptin?

Across 329 Part D plans, Saxagliptin averages $1.43/unit (NADAC). Lowest available: $1.34/unit. Highest in distribution: $1.52/unit.

Is Saxagliptin on the FDA shortage list?

No. Saxagliptin is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (12 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.